Knowledge of SARS-CoV-2 Epitopes and Population HLA Types Is Important in the Design of COVID-19 Vaccines

Rafidah Lani 1, Nurul Aqidah Senin 2, Sazaly AbuBakar 3 and Pouya Hassandarvish 3,*

1 Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia
2 Department of Biomedical Sciences, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia
3 Tropical Infectious Diseases Research & Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur 50603, Malaysia
* Correspondence: pouyahassandarvish@um.edu.my; Tel.: +603-7967-6670

Abstract: The COVID-19 pandemic has caused extensive loss of lives and economic hardship. In response, infectious disease experts and vaccine developers promptly responded by bringing forth candidate vaccines, some of which have been listed in the World Health Organization’s Emergency Use Listing. Notwithstanding the diverse worldwide population genetics, the vaccines thus far developed are generic in nature for use worldwide. Differences in the human leukocyte antigen (HLA) in different populations, variation of the T cell epitopes, and the propensity of SARS-CoV-2 genetic mutations left room for improvement of the vaccines. Here, we discussed the implications of COVID-19 vaccination and SARS-CoV-2 infection by taking into consideration SARS-CoV-2 mutations, T cell epitopes, risk factors, and current platforms of candidate vaccines based on the HLA types that are commonly present in Peninsular Malaysia Chinese, Indian, and Malay populations. The HLA types associated with protection against and susceptibility to severe SARS-CoV-2 infection were identified based on reported case-control and cohort studies. The relevance of including the non-spike SARS-CoV-2 proteins in the future COVID-19 vaccines is also highlighted. This review is meant to trigger researchers to acknowledge the importance of investigating the possible relationships between the HLA haplotype and the SARS-CoV-2 strains circulating in different populations.

Keywords: infectious diseases; SARS-CoV-2; COVID-19; vaccine; T cell epitopes; human leukocyte antigens

1. Introduction

The COVID-19 pandemic has impacted our lives not only physically and mentally, but also economically. To date, approximately 580 million confirmed cases of COVID-19 and 6.4 million deaths have been recorded globally. The impact is no less devastating in Malaysia: with over 5000 confirmed cases daily, the total number of confirmed COVID-19 cases is approaching 5 million with almost 36,000 deaths [1].

The SARS-CoV-2 virus is the etiological agent responsible for several pneumonia-like cases that began in Wuhan, China [2]. Being the hub of transportation and industry for central China, the outbreak that started in early November, or December 2019, rapidly spread to become a pandemic [3]. Similar to other viruses that are transmitted through direct, indirect, or close contact with respiratory secretions or droplets from infected people [4], this Betacoronavirus spreading was greatly facilitated by international air travel [4]. The enveloped SARS-CoV-2 virus bears a large (approximately 30+ kb) single-stranded-positive sense RNA genome consisting of up to 14 open reading frames (ORFs) that are translated into the spike (S) protein, matrix (M) protein, envelope (E) protein, nucleocapsid (N) and about 16 non-structural proteins (nsps) [5]. Similar to other RNA viruses, SARS-CoV-2 also accumulates genomic mutations as it replicates owing to natural selections [6]. A number of mutations contribute to the augmented ability of the virus to replicate as well as to evade the host immune responses [6].
With the growing number of cases and the emergence of new SARS-CoV-2 mutants, infectious disease experts, epidemiologists, and public health officers have worked relentlessly to control the spread of the infection and at the same time to deduce the consequences of SARS-CoV-2 mutations. Just within a year since the COVID-19 pandemic started, vaccines have been manufactured and used by millions around the world. The exact mechanism of how SARS-CoV-2 caused severe COVID-19 disease, however, is still not known. Here, we look at the potential importance of the human leukocyte antigen (HLA) in COVID-19, Ref. [7] focusing on the multi-ethnic Malaysian population.

The Major Histocompatibility complex (MHC) system or HLA complex in humans is located on the short arm of chromosome 6 (6p21.3) [8]. Normally inherited as an en bloc from each parent in a no recombination event, linked HLA genes (HLA-A, -B, -C, -DR, -DQ, -DP) are combined as a HLA haplotype and transmitted on a single parental chromosome [9]. Abiding by its imperative functions in self-recognition, eliciting the immune response to an antigenic stimulus and to the regulation of cellular and humoral immunity, HLA class I antigens (HLA-A, -B, and -C) are expressed on the surface of all nucleated cells and platelets (except those of the central nervous system) [10] while the HLA class II antigens (HLA-DR, -DP, and -DQ) are expressed on antigen-presenting cells (APC) [10]. These highly polymorphic HLA loci are involved in antigen presentation to CD8+ T cells (HLA class I), natural killer cells, and CD4+ T cells (HLA class II) [11].

The fate of the SARS-CoV-2 virus and the outcomes of the infection are highly dependent on the efficiency of one’s immune system, particularly the T-cell immunity. Considering that the HLA haplotype occurs differently in different populations, the efficiency in SARS-CoV-2 viral clearance and disease progression in return are speculated to be varied. Studies associated with SARS-CoV-2 and HLA have focused on the involvement of cytotoxic CD8+ T and helper CD4+ T lymphocytes as their responses are vital for initial viral clearance, the development of immunologic memory, and eventually for orchestrating the adaptive immune responses [12]. In this report, we explored the potential repercussions of SARS-CoV-2 infection based on the HLA allele frequencies in the Malaysian population highlighting the HLAs that could contribute to the protection or exacerbation of SARS-CoV-2 infection.

1.1. SARS-CoV-2 Specific T Cell Epitopes

The search for potential vaccine targets has led to numerous studies to decipher the T cell epitopes that can evoke the MHC-I and MHC-II responses. In Table 1, we present the distribution of SARS-CoV-2 T cell epitopes as predicted from the combinations of the cohort (unexposed and convalescent individuals), bioinformatics, and mathematical modeling studies. Presentation of multiple SARS-CoV-2 epitopes is deemed critical in the induction of vaccine-based and natural infection immunity [13–16]. Detection of post-infectious T cell immunity is feasible through the employment of SARS-CoV-2-specific peptides even in seronegative convalescent individuals [13,17]. In the absence of antibody responses, specific T cell responses were observed in seronegative convalescent donors but not in unexposed donors, hence emphasizing the activation of T cell immunity upon infection. The SARS-CoV-2 CD4+ T cell is essential in evoking persistent and robust immune responses compared to the HLA class I T cell epitopes [13]. CD4+ T cell recognizes multiple dominant HLA-DR T cell epitopes [13]. The SARS-CoV-2 M protein was recognized by specific CD4+ T cells in COVID-19 cases [15]. The inadequacy of quality class II epitopes from the M protein is contributed to by its small size [18]. Although class II epitopes are predominantly available across the SARS-CoV-2 genomes, it appears that highly expressed proteins are preferred by memory CD4+ T cells [19].
Table 1. Distribution of CD4+ and CD8+ epitopes based on SARS-CoV-2 proteins.

| No. | Protein(s) and Their (Respective Numbers of Epitopes) | Subset | Ref. |
|-----|------------------------------------------------------|--------|------|
| 1   | N (4) non-RBD-S (90), RBD-S (23), E (2), ORF3a (7), ORF7a (3), ORF6 (7), ORF8 (4), nsp1 (1), nsp2 (7), nsp3 (11), nsp4 (10), nsp5 (4), nsp6 (9), nsp8 (2), nsp10 (2), nsp12 (9), nsp13 (4), nsp14 (4), nsp15 (1), nsp16 (2) | CD4    | [19] |
| 2   | S (29), N (15), M (27), ORF7a (1)                   | CD4    | [20] |
| 3   | S (11), N (21), ORF3a (4)                           | CD8    | [20] |
| 4   | ORF9+N (50), ORF5+M (11), ORF2+S (3), ORF3 (4), ORF4+E (1), ORF6 (1), ORF8 (6) | CD4    | [13] |
| 5   | ORF1 (4), ORF2+S (2), ORF9+N (5), ORF5+M (1)       | CD8    | [13] |
| 6   | S (1), ORF1ab (4)                                   | CD8    | [21] |
| 7   | M (2), S (5), ORF1ab (24), ORF3 (1), ORF6 (1), ORF7 (2), ORF8 (1) nsp1 (2), nsp2 (14), PLpro (34), nsp4 (22), 3CL (6), nsp6 (18), nsp7 (4), nsp8 (4), nsp9 (2), nsp10 (2), RdRp (19), Hel (14), nsp14 (19), nsp15 (4), nsp16 (9), S (20), ORF3a (10), E (8), M (8), ORF6 (6), ORF7a (4), ORF8 (3), N (7), ORF10 (1) | CD4    | [22] |
| 8   | nsp1 (13), nsp2 (40), PLpro (128), nsp4 (40), 3CL (15), nsp5 (16), nsp7 (6), nsp8 (17), nsp9 (13), nsp10 (7), RdRp (68), Hel (38), nsp14 (33), nsp15 (25), nsp16 (16), S (86), ORF3a (20), E (2), M (15), ORF6 (2), ORF7a (8), ORF8 (3), N (13), ORF10 (3) | CD8    | [22] |
| 9   | N (8), nsp7 (1)                                     | CD4    | [15] |
| 10  | N (3)                                                | CD8    | [15] |
| 11  | ORF1ab (40), M (3), S (6), N (2), ORF3a (3), ORF7a (1) | CD8    | [23] |
| 12  | ORF1ab (40), M (3), S (6), N (2), ORF3a (3), ORF7a (1) | CD8    | [23] |
| 13  | ORF1ab (1478), S (248), ORF3a (69), E (18), M (72), ORF6 (8), ORF7a (26), ORF8 (22), N (60), ORF10 (12) | CD8    | [24] |
| 14  | ORF1ab (1002), S (154), ORF3a (74), E (11), M (57), ORF6 (28), ORF7a (16) ORF8 (18), N (32), ORF10 (7) | CD4    | [24] |
| 15  | M (5), N (2), S (5)                                 | CD4    | [25] |
| 16  | N (2)                                                | CD8    | [25] |

CD4: cluster of differentiation 4; CD8: cluster of differentiation 8; N: nucleocapsid; S: spike; RBD-S: receptor-binding domain-spike; E: envelope; ORF: open reading frame; nsp: non-structural protein; M: matrix; PLpro: papain-like protease; RdRp: RNA-dependent RNA polymerase; Hel: helicase.

T cell memory responses were observed more in patients recovering from severe COVID-19 infections than mild cases, with a greater magnitude of SARS-CoV-2-specific CD8+ T cells observed in the latter [20]. Detection of spike-specific antibodies in some donors with low (receptor-binding domain) RBD-specific antibodies indicates that antibodies were capable of targeting the non-RBD regions of the spike [20]. Establishments of T cell responses in correlation with milder cases will provide insight into protective immunity [20]. On that account, immense CD8+ T cell responses (to spike, M and N proteins) were observed in donors recovering from mild forms of the disease compared to severe cases [14,20].

These findings coincided with different subsets of SARS-CoV-2-specific T cells. Cytotoxic CD4+ T cells might not be a major contributor to SARS-CoV-2 clearance, since, unlike in influenza virus infections, CD107a+ CD4+ T cells (of cytotoxic potential) are scarcely detected [20]. Incorporating non-spike proteins such as N, M, and ORFs proteins in future vaccine design is perhaps beneficial as central memory and effector memory CD8+ T cells were identified in response to those proteins [20]. Ferretti et al., acknowledged in their study that next-generation vaccines incorporated with shared SARS-CoV-2 epitopes residing outside the spike protein will not only be independent of mutational variation but will also be better at eliciting SARS-CoV-2-specific CD8+ T cell immunity [16].

Heterologous immunity in SARS-CoV-2 infection is characterized by the pre-existing T cell responses against SARS-CoV-2 peptides [13]. The immunity is cross-reactive with common cold coronaviruses in 81% of unexposed individuals [13]. Mateus et al., 2020 also demonstrated the capability of SARS-CoV-2-specific memory CD4+ T cells to cross-react with corresponding ~67% homologous sequences from any of the many different commonly circulating common cold human coronaviruses (HCoV)-OC43, -229E, -NL63, and -HKU1 [19]. However, this event seems to happen uniquely in one direction and not vice versa [19]. Despite being highly speculative and vague, the implications of
pre-existing HCOVs memory CD4+ T cells on the magnitude of SARS-CoV-2 infection are ascertained [19]. Although the magnitude of T cell responses is not associated with disease severity, severely ill patients possibly lack pre-existing SARS-CoV-2 T cells. This is demonstrated by lower recognition rates of SARS-CoV-2 T cell epitopes in individuals with more severe COVID-19 symptoms compared to non-hospitalized patients with high antibody titers [13].

While bioinformatics- and mathematical modeling-type studies have limitations of their own [21–24], cohort and case-control studies also come with some drawbacks [13–15,19,20,25]. The cohort and case-control studies discussed in this review are largely affected by the number of donors. Meticulous evaluation in comparing mild and severe cases is inconceivable without taking diverse T cell receptors, peptide-MHC affinities, and antigen sensitivities for different epitopes into consideration [13–15,19,20,25]. The significance of these factors is worthy of being addressed in future studies. Different techniques applied to determine IFN-γ-producing SARS-CoV-2-specific T cell responses yield contrasting results. This drawback is a result of detection method discrepancies as demonstrated by peptide-stimulated activation-induced marker (AIM) assays and ELISpots and ICS assays in a recent immunogenicity study of recombinant adenovirus type-5vectored COVID-19 vaccine human phase I trial [14,26]. Although both methods are valid, the functional relevance is different.

The geographical regions where the studied donors are recruited also influenced cross-reactive responses as different coronaviruses (in both humans and animals) are circulating in different populations [27–30]. Pre-existing T cells exhibiting cross-reactivity do not necessarily imply previous coronavirus infections, but they could potentially be primed by other microbes too [31]. Thus, further detailed investigations based on this factor are necessary. Furthermore, the cohort studies focused on T cell responses in PBMCs instead of memory T cells at the site of infection most likely contributes to effective protection as observed in influenza virus infection [20].

1.2. Susceptible, Severe, and Protective HLA to SARS-CoV-2 Virus Based on Malaysian Population Allele Frequencies

The HLA class I and II loci identified in SARS-CoV-2 infection and epitopes recognition garnered from referred studies [15,19–22,25,32–40] based on the Malaysian population are presented in Figures 1 and 2. We extracted the HLA phenotype frequency as shown in Figures 1 and 2; from only “gold-standard” data sets comprising Malaysia Peninsular Chinese (n = 194) [32], Indian (n = 271) [33], and Malay (n = 951) [34] populations as available at allelefrequencies.net. The data set of HLA phenotype frequency in the Malaysian population is notably insufficient as it only covered HLA-A, -B, -C, -DRB1, and -DQB1 loci. This limited data set should be considered as an indicator for more investigations to be performed on Malaysian HLA phenotype frequency as it is vital not only for infectious diseases but for other diseases too. The HLA phenotype frequencies in these three main ethnicities in Malaysia are indisputably different to some extent. For example, HLA-DRB1*11:04 and -DQB1*04:01 are distinctly absent in Malaysia’s Indian population [33].

The HLA-DRB1*11:04 and -DRB1*03:01 are associated with protection against SARS-CoV-2 infection [35–37], while the latter is also associated with susceptibility and/or severe SARS and SARS-CoV-2 (when occurred as haplotype HLA-A*:01:01g-B*:08:01g-C*:07:01g-DRB1*:03:01g) [35] infection in other studies together with HLA-DRB1*08:01, -DRB1*12:02, -DRB1*15:01 and -DQB1*06:02 [36,38]. Much as it is affected by the number of populations being studied (n), the phenotype frequency of HLA-DRB1*03:01, -DRB1*12:02, and -DRB1*15:01 are highest in Chinese, Malay, and Indian populations, respectively [32–34].
Figure 1. HLA class II phenotype frequency in Malaysia Peninsular Chinese, Indian, and Malay populations extracted from allelefrequencies.net in corresponding to SARS-CoV-2 epitopes recognition. The HLA phenotypes were collected from reported bioinformatics, case-control, and cohort studies.

Figure 2. HLA class I phenotype frequency in Malaysia Peninsular Chinese, Indian, and Malay populations extracted from allelefrequencies.net in corresponding to SARS-CoV-2 epitopes recognition. The HLA phenotypes were collected from reported bioinformatics, case-control, and cohort studies.
Out of the 35 most studied HLA class I phenotypes, six HLA phenotypes: HLA-A*02:01 (highest in Chinese) [32], -A*02:05, -B*15:03, -B*18:01 (highest in Malay) [34], -B*58:01 (highest in Chinese) [32], and -C*07:01 (highest in Malay) [34] are associated with protection [35,36,38] against SARS-CoV-2 infection and six phenotypes: HLA-A*01:01 (highest in Indian) [33], -B*07:03, -B*08:01, -B*27:07, -B*46:01 (highest in Chinese) [32] and -C*07:01 are associated with susceptibility and/or severe SARS-CoV-2 infection [35,38,39]. The HLA-C*07:01 is associated with both outcomes in studies with contradictory results. It has been reported that the haplotype ranked #1 HLA-A*01:01g-B*08:01g-C*07:01g-DRB1*03:01g shows a significant correlation in both SARS-CoV-2 infection incidence and mortality. Contrariwise, haplotype ranked #2 HLA-A*01:01g-B*18:01g-C*07:01g-DRB1*11:04g shows a negative correlation suggestive to protection [35,36]. Subject to the number of populations being studied (n), all three populations are lacking in HLA-B*07:03 [32–34], while only the Chinese appear to have deficiency in HLA-A*02:05, -B*18:01, -B*27:07, -B*44:02, and -C*02:02 [32]. Together with the Indian population, the Chinese population also lacked HLA-C*14:03 [32,33] and HLA-B*15:03 seems to be absent in the Malay population too [33,34].

The discrepancies between studies (case-control and/or cohort) pertaining to the association of HLA class I and II phenotypes with protection against; and susceptibility and/or severe SARS-CoV-2 infection are predicted to be greatly influenced by the population being studied and the alignment of the SARS-CoV-2 epitopes being used in the studies. For instance, HLA-DRB1*03:01 are associated with both protection against and susceptibility to SARS-CoV-2 infection in donors recruited from Oxford, the United Kingdom, and the Italian Bone Marrow Donor Registry (when occurred as haplotype HLA-A*:01:01g-B*08:01g-C*07:01g-DRB1*03:01g), respectively [20,35]. In addition, HLA-DRB1*03:01 is also associated with protection against SARS-CoV-1 infection in Taiwan’s healthcare workers [40].

The outcomes from studies revolving around HLA-C*07:01 point to the association of this particular phenotype to both protection against, and susceptibility toward severe SARS-CoV-2 infections [35,36]. When occurred as haplotype HLA-A*02:01g-B*18:01g-C*07:01g-DRB1*11:04g which is more frequent in the southern region of Italy, it is associated with protection against SARS-CoV-2 infection; and haplotype HLA-A*:01:01g-B*08:01g-C*07:01g-DRB1*03:01g which is more frequent in the northern region of Italy yields the opposite [35]. In another study involving a cohort in the Cagliari population (the southern region of Sardinia Island in Italy), the extended haplotype of HLA-C*07:01 is anticipated to provide protection against SARS-CoV-2 infection [36]. By scrutinizing all of the discussed studies, when it comes to investigating the relationship between HLAs and SARS-CoV-2 infection, it is desirable to begin research on SARS-CoV-2 sequences that are circulating in Malaysia, a bigger number of data set and diverse HLA phenotype in the Malaysian population; and all the more important is to identify the haplotype itself. From the two Italian studies, we can conclude that the outcome of SARS-CoV-2 infection is highly dependent on the polymorphism of particularly HLA-B*08:01, -DRB1*03:01, and -C*07:01 together with their combination with other alleles as a haplotype [35,36].

1.3. Host and Viral Factors in SARS-CoV-2 Infection

Among oft-mentioned analytical factors that are linked to SARS-CoV-2 infection, are host factors such as age [41–45], co-morbidities [46–50], and previous vaccinations [51–53] frequently brought up independently (if not investigated together with other confounding factors for example gender [54–58], demographical data [59–63], diet and exercise [64–66], past infection [67,68], food consumption [69–71], compliance with social-distance measure [72–74], etc.). A major concern is its mutation potentiality [75–77]. Age plays a substantial role as an independent risk factor for morbidity and mortality in COVID-19 patients [78–83]. This conception was proven in multivariate analyses in both Italy and China (despite their differences in mean age) where higher COVID-19 case-fatality rates were correlated with the increase in the median age [84–86]. This finding points to other indicators which are the
differential expression of angiotensin-converting enzyme (ACE2) according to age since this enzyme is expressed in vital organs and its high expression in lung tissues of higher age groups is speculated to explain clinical pathology and susceptibility to SARS-CoV-2 infection [87,88].

In the case of ACE2, conditions such as hypertension, diabetes, cardiovascular disease, and chronic obstructive pulmonary disease (COPD) are also described as risk factors [89–93]. As a receptor for SARS-CoV-2 and its vast distribution in the lung, adipose, and endothelial tissues, COVID-19 disease progression is associated with the above-mentioned co-morbidities [94,95]. The usage of an angiotensin-converting enzyme inhibitor (ACEI) and angiotensin-receptor blocker (ARB) therapy is debatable in our early endeavor with COVID-19 infections since antihypertensive medications can modulate the expression of ACE2 protein [96]. With the exclusion of ACE2 polymorphism, the genetic association with hypertension traits (hopefully) involving larger cohorts in future studies, the safety of continuing the consumption of ACEI/ARB among patients is, for now, certain [96].

The impact of SARS-CoV-2 infection on diabetic patients is also being observed. The differential expression of ACE2 protein in normal and diabetic patients was reflected by the ACE2 expression in their lung tissue, liver, and pancreas. The expression of ACE2 is higher in bronchial and alveolar [97], pancreatic islets [98], and liver [99] of subjects with diabetes compared to normal subjects. The ramifications of the increase in ACE2 expression in these three organs of diabetic patients on SARS-CoV-2 infection and COVID-19 pathology warrants further investigation. As other diseases are being hypothesized to be co-morbidities and contributing factors to the exacerbation of COVID-19 clinical outcomes, COPD is also associated with the increase in mortality rates of COVID-19 patients [100]. Together with smoking behavior, COPD sets a greater risk for progression towards severe COVID-19 outcomes [101–103].

Although previous vaccinations especially the Bacille Calmette-Guérin (BCG) vaccine extensively featured in SARS-CoV-2-related studies, researchers failed to come out with sound evidence to propose and justify the usage of BCG for prevention of COVID-19 [104]. A number of new SARS-CoV-2 variants emerging as a result of the mutation have made the efficiency of recently developed vaccines questioned by the public. A theoretical study by Agerer et al., 2021 demonstrated that the nonsynonymous point mutations in SARS-CoV-2 MHC-I-restricted epitopes enable the virus to hide from CD8+ T cell surveillance [105]. Toyoshima et al., identified in their recent findings that ORF1ab 4715L and S protein 614G variants are strongly correlated with fatality rates [76]. However worrisome the impact of SARS-CoV-2 mutations on mortality rate is, the most controversial mutations such as the ones involving spike D614G, P323L and N501Y are only responsible for higher viral load and younger age of patients; enhancement of SARS-CoV-2 transmission capacity and improvement of viral fitness in different geographical regions [106,107]. All things considered, our previous remark on including the least-mutated, non-spike, T-cell epitopes in SARS-CoV-2 vaccine development still stands.

1.4. Current Vaccine Options for SARS-CoV-2 Virus

In response to the COVID-19 pandemic, vaccine developers raced towards getting a safe and efficient vaccine through various platforms. As of February 2021, 63 candidate vaccines (with two being suspended from development) are in clinical trial phases and 174 are in pre-clinical evaluations [108]. Among the candidate vaccines, about 32% or the plurality of the candidates are developed using protein subunit platform and the rest are non-replicating viral-vector (VVnr,16%), DNA (13%), inactivated virus (14%), RNA (11%), replicating viral-vector (VVr, 5%), virus-like particle (3%), VVr + antigen-presenting cell (3%), live-attenuated virus (2%) and VVnr + antigen-presenting cell (2%) [108].

Conventionally, two doses of vaccines (60% of the candidates) are required with a 14, 21, or 28 days interval in adherence to the prime-boost regimen, while 19% of the candidate vaccines only require one dose and 2% require three doses with the administration on day 0, 28 and 56 [108]. Most of the candidate vaccines are administered intramuscularly (76%),
whereas 5% are intradermal and 3% are subcutaneous [108]. Currently, at the dawn of its pre-clinical development, two potential candidate vaccines are deemed to be convenient for vaccination as they are to be administered intranasally (Coroflu) [109] and as a skin patch (PittCoVac) [110], if successful. Recently, WHO has added five vaccines; BNT162 (Pfizer, USA), mRNA-1273 (Moderna, Cambridge, MA, USA), AZD-1222 (SK BIO, Seongnam, Korea), ChAdOx1_nCoV-19 (Serum Institute of India, Pune, India) and Ad26.COV2.S (Johnson & Johnson, New Brunswick, NJ, USA), into their Emergency Use Listing (EUL) for COVID-19 pandemic as the procedure, which has also served for the West Africa Ebola outbreak (2014–2016) [111]. More candidate vaccines that are listed in WHO EUL/PQ (prequalification) evaluation process are still waiting for a decision.

Similar to other countries, Malaysia started its National COVID-19 Immunisation Programme at the end of February 2021, immediately after acquiring five COVID-19 vaccines; BNT162 (Pfizer, New York, NY, USA), AZD-1222 (AstraZeneca, London, UK), CoronaVac (Sinovac, Beijing, China), Ad5-nCoV (CanSinoBIO, Tianjin, China), and Sputnik V (Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia) [112]. A total of 66.7 million doses were to cover 109.65% of those in the country in three phases [112]. Albeit short-lasting, mild to moderate COVID-19 vaccine side effects were anticipated and have been reported. Rare adverse events were also proclaimed however irrelevant the events were to the to COVID-19 vaccines. As of March 2021, 7 cases of blood clots in multiple blood vessels (disseminated intravascular coagulation, DIC) and 18 cases of cerebral venous sinus thrombosis (CVST) have been reviewed by European Medicines Agency (EMA)’s Pharmacovigilance Risk Assessment Committee (PRAC), out of 20 million vaccinated people in the United Kingdom and European Economic Area.113 However, a causal link between these events and AstraZeneca’s COVID-19 vaccine is still not proven and its benefits still outweigh the risks although these events deserve further investigation [113].

Contemplating our genetic make-up, the genetic risk factors that might contribute to severe COVID-19 disease and severe post-vaccination side effects should also be considered. For example, the hypertension traits in human chromosomes as well as Factor V Leiden which is the most common form of inherited thrombophilia with the highest occurrence of heterozygosity rate in Europe [114–117]. Before denouncing COVID-19 vaccines, it is wiser to consider all plausible explanations and reasons that originate from risk factors around us.

2. Conclusions

Considering most of the vaccines were developed with spike protein and this protein is prone to mutation, there is always room for improvement. By considering the SARS-CoV-2 T cell epitopes and the HLAs that are associated with protection against, and/or associated with susceptibility/severity to SARS-CoV-2 infection; the future COVID-19 vaccine design is expected to be developed based on the non-spike proteins such as NP, M, and ORFs. As highlighted in this perspective review, investigating the polymorphism of HLA-B*08:01, -DRB1*03:01, and -C*07:01 in a population is crucial as the outcomes of COVID-19 disease and vaccination are highly dependent on these alleles. Together with potential pre-existing cross-reactive T cell immunity to SARS-CoV-2, the performance of this future vaccine could provide better COVID-19 clinical outcomes and influence the herd immunity of all epidemiological models.

Author Contributions: Conceptualization, R.L. and P.H.; validation, R.L., P.H. and S.A.; formal analysis, R.L.; investigation, R.L. and N.A.S.; resources, R.L.; data curation, R.L.; writing—original draft preparation, R.L.; writing—review and editing, P.H and S.A.; funding acquisition, S.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Ministry of Higher Education for niche research under the Higher Institution Centre of Excellence (HiCoE) program, Project Code: MO002-2019.

Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We acknowledge the funding from the Ministry of Higher Education, Malaysia for niche area research under the Higher Institution Centre of Excellence (HICoE) program (Project MO002-2019). We would like to acknowledge the staff of Tropical Infectious Disease Research and Education Center (TIDREC) and the staff of the Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya for their unwavering support throughout this study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. World Health Organization Coronavirus Disease (COVID-19) Dashboard. Available online: covid19.who.int (accessed on 12 October 2020).

2. Sangeeta, D.; Deepiyoti, K. Wuhan Coronavirus: A fast-emerging global threat. Int. J. Health Res. Med. Leg. Pract. 2020, 6, 79–82. [CrossRef]

3. Heisbourg, F. From Wuhan to the world: How the pandemic will Reshape Geopolitics. Survival 2020, 62, 7–24. [CrossRef]

4. Choi, E.M.; Chu, D.K.; Cheng, P.K.; Tsang, D.N.; Peiris, M.; Bausch, D.G.; Poon, L.L.; Watson-Jones, D. In-flight transmission of SARS-CoV-2. Emerg. Infect. Dis. 2020, 26, 2713. [CrossRef]

5. Chen, L.; Zhong, L. Genomics functional analysis and drug screening of SARS-CoV-2. Genes Dis. 2020, 7, 542–550. [CrossRef]

6. Lawton, G. The coronavirus evolves. New Sci. 2021, 249, 8–9. [CrossRef]

7. Requena, D.; Médico, A.; Chacón, R.D.; Ramírez, M.; Marin-Sánchez, O. Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country. Front. Immunol. 2020, 11, 2008. [CrossRef]

8. Trowsdale, J. Genetic and functional relationships between MHC and NK receptor genes. Immunity 2001, 15, 363–374. [CrossRef]

9. Shankarkumar, U. The human leukocyte antigen (HLA) system. Int. J. Hum. Genet. 2000, 27, 1095–1107. [CrossRef]

10. Khanolkar, A.; Badovinac, V.P.; Harty, J.T. CD8 T cell memory development: CD4 T cell help is appreciated. Immunol. Res. 2004, 31, 1489–1501. [CrossRef]

11. Le Bert, N.; Tan, A.T.; Kunasegaran, K.; Tham, C.Y.; Hafezi, M.; Chia, A.; Chng, M.H.; Lin, M.; Tan, N.; Linster, M.; et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 2020, 181, 1849–1851. [CrossRef]

12. Ferretti, A.P.; Kula, T.; Wang, Y.; Nguyen, D.M.; Weinheimer, A.; Dunlap, G.S.; Xu, Q.; Nabilsi, N.; Perullo, C.R.; Cristofaro, A.W.; et al. Unbiased screens show CD8+ T cells of COVID-19 patients recognize shared epitopes in SARS-CoV-2 that largely reside outside the spike protein. Immunity 2020, 53, 1095–1107. [CrossRef]

13. Sekine, T.; Perez-Potti, A.; Rivera-Ballesteros, O.; Strålin, K.; Gorin, J.B.; Olsson, A.; Llewellyn-Lacey, S.; Kamal, H.; Bogdanovic, G.; Muschiol, S.; et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 2020, 183, 158–168. [CrossRef]

14. Klein, S.; Cortese, M.; Winter, S.L.; Wachsmuth-Melm, M.; Neufeldt, C.J.; Cerikan, B.; Stanifer, M.L.; Boulant, S.; Bartenschlager, R.; Chlanda, P. SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography. Nat. Commun. 2020, 11, 5885. [CrossRef]

15. Mateus, J.; Grifoni, A.; Tarke, A.; Sidney, J.; Ramirez, S.I.; Dan, J.M.; Burger, Z.C.; Rawlings, S.A.; Smith, D.M.; Phillips, E.; et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 2020, 370, 89–94. [CrossRef]

16. Peng, Y.; Mentzer, A.J.; Liu, G.; Yao, X.; Yin, Z.; Dong, D.; Dejinirattisai, W.; Rostron, T.; Supasa, P.; Liu, C.; et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 2020, 21, 1336–1345. [CrossRef]

17. Crooke, S.N.; Ovsyannikova, I.G.; Kennedy, R.B.; Poland, G.A. Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome. Sci. Rep. 2020, 10, 1–5. [CrossRef]

18. Grifoni, A.; Sidney, J.; Zhang, Y.; Scheuermann, R.H.; Peters, B.; Sette, A. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe 2020, 27, 671–680. [CrossRef] [PubMed]
23. Yarkovich, M.; Warrington, J.M.; Farrel, A.; Maris, J.M. Identification of SARS-CoV-2 vaccine epitopes predicted to induce long-term population-scale immunity. *Cell Rep. Med.* **2020**, 1, 100036. [CrossRef] [PubMed]

24. Kiyotani, K.; Toyoshima, Y.; Nemoto, K.; Nakamura, Y. Bioinformatic prediction of potential T cell epitopes for SARS-CoV-2. *J. Hum. Genet.* **2020**, 65, 569–575. [CrossRef]

25. Keller, M.D.; Harris, K.M.; Jensen-Wachspress, M.A.; Kankate, V.V.; Lang, H.; Lazarski, C.A.; Durkee-Shock, J.; Lee, P.H.; Chaudhry, K.; Webber, K.; et al. SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. *Blood* **2020**, 136, 2905–2917. [CrossRef] [PubMed]

26. Braun, J.; Loyal, L.; Frentsch, M.; Wendisch, D.; Georg, P.; Kurth, F.; Hippensiel, S.; Dingeldey, M.; Kruse, B.; Fauchere, F.; et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. *Nature* **2020**, 587, 270–274. [CrossRef]

27. Lipsitch, M.; Grad, Y.H.; Sette, A.; Crotty, S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. *Nat. Rev. Immunol.* **2020**, 20, 709–713. [CrossRef]

28. Sette, A.; Crotty, S. Pre-existing immunity to SARS-CoV-2: The knowns and unknowns. *Nat. Rev. Immunol.* **2020**, 20, 457–458. [CrossRef]

29. Ng, K.W.; Faulkner, N.; Cornish, G.H.; Rosa, A.; Harvey, R.; Hussain, S.; Ulferts, R.; Earl, C.; Wrobel, A.G.; Benton, D.J.; et al. Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans. *Science* **2020**, 370, 1339–1343. [CrossRef]

30. Gombar, S.; Bergquist, T.; Pejaver, V.; Hammarlund, N.E.; Murugesan, K.; Mooney, S.; Shah, N.; Pinsky, B.A.; Banaei, N. SARS-CoV-2 infection in healthy adults. *Swiss. Med. Wkly.* **2020**, 150, 2169–2173. [CrossRef] [PubMed]

31. Anderson, E.M.; Goodwin, E.C.; Verma, A.; Arevalo, C.P.; Bolton, M.J.; Weirick, M.E.; Gouma, S.; McAllister, C.M.; Christensen, S.R.; Weaver, J.; et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. *Cell* **2021**, 184, 1–7. [CrossRef]

32. Too, C.L.; Tan, L.K.; Heselynn, H.; Nor-Shuhaila, S.; Eashwary, M.; Wahinuddin, S.; Lau, S.; Gun, S.C.; Mohd-Shahrir, M.S.; Ainon, M.M.; et al. HLA-A,-B,-C,-DRB1 and -DQB1 alleles and haplotypes in 194 Southeast Asia Chinese from Peninsular Malaysia. *Hum. Immunol.* **2019**, 80, 906–907. [CrossRef] [PubMed]

33. Nurul-Aain, A.F.; Tan, L.K.; Heselynn, H.; Nor-Shuhaila, S.; Eashwary, M.; Wahinuddin, S.; Lau, S.; Gun, S.C.; Mohd-Shahrir, M.S.; Ainon, M.M.; et al. HLA-A,-B,-C,-DRB1 and -DQB1 alleles and haplotypes in 271 Southeast Asia Indians from Peninsular Malaysia. *Hum. Immunol.* **2020**, 81, 263–264. [CrossRef] [PubMed]

34. Tan, L.K.; Mohd-Farid, B.; Salsabil, S.; Heselynn, H.; Wahinuddin, S.; Lau, S.; Gun, S.C.; Nor-Suhaila, S.; Eashwary, M.; Mohd-Shahrir, M.S.; et al. HLA-A,-B,-C,-DRB1 and -DQB1 alleles and haplotypes in 951 Southeast Asia Malays from Peninsular Malaysia. *Hum. Immunol.* **2016**, 77, 818–819. [CrossRef] [PubMed]

35. Pisanti, S.; Deelen, J.; Gallina, A.M.; Caputo, M.; Citro, M.; Abate, M.; Sacchi, N.; Vecchione, C.; Martinelli, R. Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of COVID-19. *J. Transl. Med.* **2020**, 18, 1–6. [CrossRef]

36. Littera, R.; Campagna, M.; Deidda, S.; Angioni, G.; Cipri, S.; Melis, M.; Firinu, D.; Santus, S.; Lai, A.; Porcella, R.; et al. Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience. *Front. Immunol.* **2020**, 11, 3320. [CrossRef] [PubMed]

37. Wang, S.F.; Chen, K.H.; Chen, M.; Li, W.Y.; Chen, Y.J.; Tsao, C.H.; Yen, M.Y.; Huang, J.C.; Chen, Y.M. Human leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection. *Viral. Immunol.* **2011**, 24, 421–426. [CrossRef]

38. Tavasolian, F.; Rashidi, M.; Hatam, G.R.; Jeddi, M.; Hosseini, A.Z.; Mosawi, S.H.; Abdollahi, E.; Inman, R.D. HLA class-I genotype in SARS-CoV-2 infected children. *J. Hum. Genet.* **2020**, 65, 818–819. [CrossRef] [PubMed]

39. Iturrieta-Zuazo, I.; Rita, C.G.; García-Soidán, A.; De Malet Pintos-Fonseca, A.; Alonso-Alarcón, N.; Pariente-Rodriguez, R.; Tejeda-Velarde, A.; Serrano-Villar, S.; Castañer-Alabau, J.L.; Nieto-Gañán, I. Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of COVID-19 Spanish patients. *Clin. Immunol.* **2020**, 219, 108572. [CrossRef] [PubMed]

40. Sanchez-Mazas, A. HLA studies in the context of coronavirus outbreaks. *Swiss. Med. Wkly.* **2020**, 150, w20248. [CrossRef] [PubMed]

41. Lu, X.; Zhang, L.; Du, H.; Zhang, J.; Li, Y.Y.; Qu, J.; Zhang, W.; Wang, Y.; Bao, S.; Li, Y.; et al. SARS-CoV-2 infection in children. *N. Engl. J. Med.* **2020**, 382, 1663–1665. [CrossRef]

42. Goldstein, E.; Lipsitch, M.; Cevik, M. On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community. *J. Infect. Dis.* **2021**, 223, 362–369. [PubMed]

43. Ellington, S.; Strid, P.; Tong, V.T.; Woodworth, K.; Galang, R.R.; Zambroano, L.D.; Nahabedian, J.; Anderson, K.; Gilboa, S.M. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–June 7, 2020. *Morb. Mortal. Wkly. Rep.* **2020**, 69, 769. [CrossRef] [PubMed]

44. O’Driscoll, M.; Dos Santos, G.R.; Wang, L.; Cummings, D.A.; Azman, A.S.; Paireau, J.; Fontanet, A.; Cauchemez, S.; Salje, H. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature* **2021**, 590, 140–145. [CrossRef]

45. Ayoub, H.H.; Chemaitelly, H.; Seedat, S.; Muntaz, G.R.; Makhoul, M.; Abu-Raddad, L.J. Age could be driving variable SARS-CoV-2 epidemic trajectories worldwide. *PLoS ONE* **2020**, 15, e0237959. [CrossRef] [PubMed]

46. Wehl, G.; Laible, M.; Rauchenzauner, M. Co-infection of SARS-CoV-2 and influenza A in a pediatric patient in Germany. *klin. pädiatr.* **2020**, 232, 217–218. [CrossRef] [PubMed]
47. Pinato, D.J.; Lee, A.J.; Biello, F.; Seguí, E.; Carbó, A.; Bruna, R.; Bower, M.; Rizzo, G.; Benafíd, S.; Carmona, C.; et al. Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe. *Cancers* **2020**, *12*, 1841. [CrossRef]

48. Eger, K.; Hashimoto, S.; Braunstahl, G.J.; Ten Brinke, A.; Patberg, K.W.; Beukert, A.; Smeenk, F.; Weersink, E.J.; Bel, E.H. Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy. *Respir. Med.* **2021**, *177*, 106287. [CrossRef]

49. Maggiolo, F.; Zoboli, F.; Arosio, M.; Valenti, D.; Guarneri, D.; Sangiorgiò, L.; Ripamonti, D.; Callegaro, A. SARS-CoV-2 infection in persons living with HIV: A single center prospective cohort. *J. Med. Virol.* **2021**, *93*, 1145–1149. [CrossRef]

50. Yao, Q.; Wang, P.; Wang, X.; Qi, G.; Meng, M.; Tong, X.; Bai, X.; Ding, M.; Liu, W.; Liu, K.; et al. Retrospective study of risk factors for severe SARS-CoV-2 infections in hospitalized adult patients. *Pol. Arch. Intern. Med.* **2020**, *130*, 390–399. [CrossRef]

51. Toraih, E.A.; Sedhom, J.A.; Dokunmu, T.M.; Hussein, M.H.; Ruiz, E.M.; Muthusamy, K.; Zerfaoui, M.; Kandii, E. Hidden in plain sight: The effects of BCG vaccination in the COVID-19 pandemic. *J. Med. Virol.* **2021**, *93*, 1950–1966. [CrossRef]

52. Reche, P.A. Potential cross-reactive immunity to SARS-CoV-2 from common human pathogens and vaccines. *Front. Immunol.* **2020**, *11*, 2694. [CrossRef] [PubMed]

53. Anbarasu, A.; Ramaiah, S.; Livingstone, P. Vaccine repurposing approach for preventing COVID 19: Can MMR vaccines reduce morbidity and mortality? *Hum. Vaccin. Immunother.* **2020**, *16*, 2217–2218. [CrossRef] [PubMed]

54. Bonafè, M.; Prattichizzo, F.; Giuliani, A.; Storci, G.; Sabbatinielli, J.; Olivieri, F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. *Cytokine Growth Factor Rev.* **2020**, *53*, 33–37. [CrossRef]

55. Vishvkarma, R.; Rajender, S. Could SARS-CoV-2 affect male fertility? *Andrology* **2020**, *52*, e13712. [CrossRef] [PubMed]

56. Conti, P.; Younes, A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: Clinical response to viral infection. *J. Biol. Regul. Homeost. Agents.* **2020**, *34*, 339–348. [PubMed]

57. Wu, C.; Yang, W.; Wu, X.; Zhang, T.; Zhao, Y.; Ren, W.; Xia, J. Clinical manifestation and laboratory characteristics of SARS-CoV-2 infection in pregnant women. *Virol. Sin.* **2020**, *35*, 305–310. [CrossRef] [PubMed]

58. Flannery, D.D.; Gouma, S.; Dhudasia, M.B.; Mukhopadhyay, S.; Pfeifer, M.R.; Woodford, E.C.; Gerber, J.S.; Arevalo, C.P.; Bolton, M.J.; Weirick, M.E.; et al. SARS-CoV-2 seroprevalence among parturient women in Philadelphia. *Sci. Immunol.* **2020**, *5*, eabd5079. [CrossRef]

59. Stringhini, S.; Niwa, A.; Piumatti, G.; Azman, A.S.; Lauer, S.A.; Baysson, H.; De Ridder, D.; Petrovic, D.; Schrempt, S.; Marcus, K.; et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCOP-POP): A population-based study. *Lancet* **2020**, *396*, 313–319. [CrossRef]

60. Bajema, K.L.; Wiegand, R.E.; Cuffe, K.; Patel, S.V.; Iachan, R.; Lim, T.; Lee, A.; Moyse, D.; Havers, F.P.; Harding, L.; et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. *JAMA Intern. Med.* **2020**, *181*, 450–460. [CrossRef]

61. Britton, T.; Ball, F.; Trapman, P. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2. *Science* **2020**, *369*, 846–849. [CrossRef]

62. Arora, R.K.; Joseph, A.; Van Wyk, J.; Rocco, S.; Atmaja, A.; May, E.; Yan, T.; Bobrovitz, N.; Chevrier, J.; Cheng, M.P.; et al. SeroTracker: A global SARS-CoV-2 seroprevalence dashboard. *Lancet Infect. Dis.* **2020**, *21*, e75–e76. [CrossRef]

63. Gudbjartsson, D.F.; Helgason, A.; Jonsson, H.; Magnusson, O.T.; Melsted, P.; Norddahl, G.L.; Saemundsdottir, J.; Sigurdsson, A.; Sulem, P.; Agustsdottir, E.; et al. Spread of SARS-CoV-2 in the Icelandic population. *N. Engl. J. Med.* **2020**, *382*, 2302–2315. [CrossRef] [PubMed]

64. Wang, M.; Baker, J.S.; Quan, W.; Shen, S.; Fekete, G.; Gu, Y. A preventive role of exercise across the coronavirus 2 (SARS-CoV-2) pandemic. *Front. Physiol.* **2020**, *11*, 572718. [CrossRef] [PubMed]

65. Chesnutt, W.M.; MacDonald, S.; Wambier, C.G. Could diet and exercise reduce risk of COVID-19 syndemic? *Med. Hypotheses* **2021**, *148*, 110502. [CrossRef] [PubMed]

66. Khaleb, M.B.; Benajiba, N. The role of nutrition in strengthening immune system against newly emerging viral diseases: Case of SARS-CoV-2. *N. Afr. J. Food Nutr. Res.* **2020**, *4*, 280–284. [CrossRef]

67. Shah, V.K.; Firmal, P.; Alam, A.; Ganguly, D.; Chattopadhyay, S. Overview of immune response during SARS-CoV-2 infection: Lessons from the past. *Front. Immunol.* **2020**, *11*, 1949. [CrossRef] [PubMed]

68. Jordan, R.E.; Adap, P. Who is most likely to be infected with SARS-CoV-2? *Lancet Infect. Dis.* **2020**, *20*, 995–996. [CrossRef]

69. Barazzoni, R.; Bischoff, S.C.; Breda, J.; Wickramasinghe, K.; Krznaric, Z.; Nitzan, D.; Pirlich, M.; Singer, P. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. *Clin. Nutr.* **2020**, *39*, 1631–1638. [CrossRef]

70. Pironi, L.; Sasdelli, A.S.; Ravaioli, F.; Baracco, B.; Battaila, C.; Bocedi, G.; Brodosi, L.; Leoni, L.; Mari, G.A.; Musio, A. Malnutrition and nutritional therapy in patients with SARS-CoV-2 disease. *Clin. Nutri.* **2021**, *40*, 1330–1337. [CrossRef]

71. Jacob, M.C.; Feitosa, I.S.; Albuquerque, U.P. Animal-based food systems are unsafe: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) fosters the debate on meat consumption. *Public Health Nutr.* **2020**, *23*, 3250–3255. [CrossRef]

72. Michie, S.; West, R.; Rogers, M.B.; Bonell, C.; Rubin, G.J.; Amlôt, R. Reducing SARS-CoV-2 transmission in the UK: A behavioural science approach to identifying options for increasing adherence to social distancing and shielding vulnerable people. *Br. J. Health Psychol.* **2020**, *25*, 945–956. [CrossRef] [PubMed]

73. West, R.; Michie, S.; Rubin, G.J.; Amlôt, R. Applying principles of behaviour change to reduce SARS-CoV-2 transmission. *Nat. Hum. Behav.* **2020**, *4*, 451–459. [CrossRef] [PubMed]
74. Doung-Ngern, P.; Suphanichaimat, R.; Panjangampatthana, A.; Janekrongtham, C.; Ruampoon, D.; Daochaeng, N.; Eungkanit, N.; Pisitpayat, N.; Srisong, N.; Yasopa, O.; et al. Case-control study of use of personal protective measures and risk for SARS-CoV-2 infection, Thailand. Emerg. Infect. Dis. 2020, 26, 2607. [CrossRef] [PubMed]

75. Benedetti, F.; Pachetti, M.; Marinii, B.; Ippodrino, R.; Ciccuzzi, M.; Zella, D. SARS-CoV-2: March toward adaptation. J. Med. Virol. 2020, 92, 2274–2276. [CrossRef] [PubMed]

76. Toyoshima, Y.; Nemoto, K.; Matsumoto, S.; Nakamura, Y.; Kiyotani, K. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. J. Hum. Genet. 2020, 65, 1075–1082. [CrossRef]

77. Abdullahi, I.N.; Emeribe, A.U.; Mustapha, J.O.; Fasogbon, S.A.; Ofor, I.B.; Opeyemi, I.S.; Obi-George, C.; Sunday, A.O.; Nwoje, J. Exploring the genetics, ecology of SARS-CoV-2 and climatic factors as possible control strategies against COVID-19. Infec. Med. 2020, 28, 166–173.

78. Ho, F.K.; Petermann-Rocha, F.; Gray, S.R.; Jari, B.D.; Katikireddi, S.V.; Niedzwiedz, C.L.; Foster, H.; Hastie, C.E.; Mackay, D.F.; Gill, J.M.; et al. Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants. PLoS ONE 2020, 15, e0241824. [CrossRef]

79. D’ascanio, M.; Innammorato, M.; Pasquariello, L.; Pizzirusso, D.; Guerrieri, G.; Castelli, S.; Pezzuto, A.; Anibaldi, P.; Marcolongo, A.; Mancini, R.; et al. Age is not the only risk factor in COVID-19: The role of comorbidities and of long staying in residential care homes. BMC Geriatr. 2021, 21, 63. [CrossRef]

80. Noor, F.M.; Islam, M.M. Prevalence and associated risk factors of mortality among COVID-19 patients: A meta-analysis. J. Community Health 2020, 45, 1270–1282. [CrossRef]

81. Biswas, M.; Rahaman, S.; Biswas, T.K.; Haque, Z.; Ibrahim, B. Association of sex, age, and comorbidities with mortality in COVID-19 patients: A systematic review and meta-analysis. Intervirology 2020, 64, 1–2. [CrossRef]

82. Wu, C.; Chen, X.; Cai, Y.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; Zhang, Y.; et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020, 180, 934–943. [CrossRef] [PubMed]

83. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062. [CrossRef]

84. Onder, G.; Rezza, G.; Brusaferro, S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020, 323, 1775–1776. [PubMed]

85. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [PubMed]

86. Grasselli, G.; Zangrillo, A.; Zane, A.; Antonelli, M.; Cabrini, L.; Castelli, A.; Cereda, D.; Coluccello, A.; Fritti, G.; Fumagalli, R.; et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020, 323, 1574–1581. [CrossRef]

87. Pagani, G.; Conti, F.; Giacomelli, A.; Bernacchia, D.; Rondanin, R.; Prina, A.; Scolari, V.; Gandolfi, C.; Castaldi, S.; Marano, G.; et al. Sero-prevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening. J. Infect. 2020, 81, e10. [CrossRef]

88. Romagnoli, S.; Peris, A.; De Gaudio, A.R.; Geppetti, P. SARS-CoV-2 and COVID-19: From the bench to the bedside. Physiol. Rev. 2020, 100, 1455–1466. [CrossRef]

89. Wu, Z.; McGoogan, J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020, 323, 1239–1242. [CrossRef]

90. Bosso, M.; Thanaraj, T.A.; Abu-Farha, M.; Alhanbi, M.; Abubaker, J.; Al-Mulla, F. The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. Mol. Ther. Methods Clin. Dev. 2020, 18, 321–327. [CrossRef]

91. Pal, R.; Bhusali, A. COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Res. Clin. Pract. 2020, 162, 108132. [CrossRef]

92. Wick, Z.; Ey前列, C.; Jakubik, D.; Simões, S.N.; Martins, D.C.; Pavão, R.; Siller-Matula, J.M.; Postula, M. ACE2 interaction networks in COVID-19: A physiological framework for prediction of outcome in patients with cardiovascular risk factors. J. Clin. Med. 2020, 9, 3743. [CrossRef] [PubMed]

93. Leung, J.M.; Niikura, M.; Yang, C.W.; Sin, D.D. COVID-19 and COPD. Eur. Respir. J. 2020, 56, 2002108. [CrossRef] [PubMed]

94. Bourgonje, A.R.; Abdulle, A.E.; Timens, W.; Hillebrands, J.L.; Navis, G.J.; Gordijn, S.J.; Bolling, M.C.; Dijkstra, G.; Voors, A.A.; Osterhaus, A.D.; et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J. Pathol. 2020, 251, 228–248. [CrossRef] [PubMed]

95. Rathnasinghe, R.; Jangra, S.; Cupic, A.; Martinez-Romero, C.; Mulder, L.C.; Kahrer, T.; Yildiz, S.; Choi, A.; Mena, I.; De Vrieze, J.; et al. The N501Y mutation in SARS-CoV-2: susceptibility to obesity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. medRxiv 2021, 9592. [CrossRef]

96. Devaux, C.A.; Rolain, J.M.; Raoult. D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J. Microbiol. Immunol. Infect. 2020, 53, 425. [CrossRef]

97. Wijnant, S.R.; Jacobs, M.; Van Eckhoutte, H.P.; Lapauw, B.; Joos, G.F.; Bracke, K.R.; Brusselle, G.G. Expression of ACE2, the SARS-CoV-2 receptor, in lung tissue of patients with type 2 diabetes. Diabetes 2020, 69, 2691–2699. [CrossRef]
98. Taneera, J.; El-Huneidi, W.; Hamad, M.; Mohammed, A.K.; Elaraby, E.; Hachim, M.Y. Expression profile of SARS-CoV-2 host receptors in human pancreatic islets revealed upregulation of ACE2 in diabetic donors. *Biology* 2020, 9, 215. [CrossRef]

99. Soldo, J.; Heni, M.; Königrainer, A.; Häring, H.U.; Birkenfeld, A.L.; Peter, A. Increased Hepatic ACE2 Expression in NAFL and Diabetes—A Risk for COVID-19 Patients? *Diabetes Care* 2020, 43, e134–e136. [CrossRef]

100. Higham, A.; Singh, D. Increased ACE2 expression in bronchial epithelium of COPD patients who are overweight. *Obesity* 2020, 28, 1586–1589. [CrossRef]

101. Sharif-Askari, N.S.; Sharif-Askari, F.S.; Alamed, M.; Temsah, M.H.; Al Heialy, S.; Hamid, Q.; Halwani, R. Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD. *Mol. Ther. Methods Clin. Dev.* 2020, 18, 1–6. [CrossRef]

102. Eapen, M.S.; Lu, W.; Hackett, T.L.; Singhera, G.K.; Thompson, I.E.; McAlinden, K.D.; Hardikar, A.; Weber, H.C.; Haug, G.; Wark, P.A.; et al. Dysregulation of endocytic machinery and ACE2 in small airways of smokers and COPD patients can augment their susceptibility to SARS-CoV-2 (COVID-19) infections. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2021, 320, L158–L163. [CrossRef] [PubMed]

103. Jacobs, M.; Van Eeckhoutte, H.P.; Wijnant, S.R.; Janssens, W.; Joos, G.F.; Brusselle, G.G.; Bracke, K.R. Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. *Eur. Respir. J.* 2020, 56, 2002378. [CrossRef] [PubMed]

104. Riccò, M.; Gualerzi, G.; Ranzieri, S.; Bragazzi, N.L. Stop playing with data: There is no sound evidence that Bacille Calmette-Guérin may avoid SARS-CoV-2 infection (for now). *Acta Biomed.* 2020, 91, 207. [PubMed]

105. Agerer, B.; Koblischke, M.; Gudipati, V.; Montaño-Gutierrez, L.F.; Smyth, M.; Popa, A.; Genger, J.W.; Endler, L.; Florian, D.M.; Mühlgrabner, V.; et al. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses. *Sci. Immunol.* 2021, 6, eabg6461. [CrossRef] [PubMed]

106. Volz, E.; Hill, V.; McCrone, J.T.; Price, A.; Jorgensen, D.; O’Toole, Á.; Southgate, J.; Johnson, R.; Jackson, B.; Nascimento, F.F.; et al. Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity. *Cell* 2021, 184, 64–75. [CrossRef] [PubMed]

107. Xie, X.; Liu, Y.; Liu, J.; Zhang, X.; Zou, J.; Fontes-Garfias, C.R.; Xia, H.; Swanson, K.A.; Cooper, D.; et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nat. Med.* 2021, 27, 620–621. [CrossRef]

108. World Health Organization. R&D Blueprint and COVID-19. Draft Landscape and Tracker of COVID-19 Candidate Vaccines. Available online: www.who.int/teams/blueprint/covid-19 (accessed on 2 February 2021).

109. Chakraborty, C.; Agoramoorthy, G. India’s cost-effective COVID-19 vaccine development initiatives. *Vaccine* 2020, 38, 7883. [CrossRef]

110. Gupta, J.; Gupta, R.; Vanshita. Microneedle Technology: An Insight into Recent Advancements and Future Trends in Drug and Vaccine Delivery. *Assay Drug Dev Technol.* 2020, 19. [CrossRef]

111. World Health Organization. Coronavirus Disease (COVID-19) Pandemic-Emergency Use Listing Procedure (EUL). Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process. Available online: extranet.who.int (accessed on 8 October 2020).

112. National COVID-19 Immunisation Programme. The Special Committee for Ensuring Access to COVID-19 Vaccine Supply (JKJAV) 2021. Available online: www.covidnow.moh.my (accessed on 13 September 2021).

113. European Medicines Agency-Pharmacovigilance Risk Assessment Committee. COVID-19 Vaccine AstraZeneca: Benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. 2021. Available online: www.ema.europa.eu (accessed on 19 March 2021).

114. Teixeira, S.K.; Pereira, A.C.; Krieger, J.E. Genetics of resistant hypertension: The missing heritability and opportunities. *Curr. Hypertens Rep.* 2018, 20, 48. [CrossRef]

115. Rossi, G.P.; Ceolotto, G.; Carocci, B.; Lenzini, L. Genetic screening in arterial hypertension. *Nat Rev. Endocrinol.* 2017, 13, 289–298. [CrossRef]

116. Ciccarelli, M.; Finelli, R.; Rivera, N.; Santulli, G.; Izzo, R.; De Luca, N.; Rozza, F.; Ceccarelli, M.; Pagnotta, S.; Uliano, F.; et al. The possible role of chromosome X variability in hypertensive familiarity. *J. Hum. Hypertens.* 2017, 31, 37–42. [CrossRef] [PubMed]

117. Kujovitch, J. Factor V Leiden thrombophilia. *Genet. Med.* 2011, 13, 1–16. [CrossRef] [PubMed]